0001415889-24-010503.txt : 20240408
0001415889-24-010503.hdr.sgml : 20240408
20240408171717
ACCESSION NUMBER: 0001415889-24-010503
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240404
FILED AS OF DATE: 20240408
DATE AS OF CHANGE: 20240408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tessari Eben
CENTRAL INDEX KEY: 0001867899
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38492
FILM NUMBER: 24830475
MAIL ADDRESS:
STREET 1: C/O KINIKSA PHARMACEUTICALS LTD.
STREET 2: CLARENDON HOUSE, 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
FORMER NAME:
FORMER CONFORMED NAME: Tessan Eben
DATE OF NAME CHANGE: 20210616
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd.
CENTRAL INDEX KEY: 0001730430
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
BUSINESS PHONE: 7814399100
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
4
1
form4-04082024_090409.xml
X0508
4
2024-04-04
0001730430
Kiniksa Pharmaceuticals, Ltd.
KNSA
0001867899
Tessari Eben
C/O KINIKSA PHARMACEUTICALS, LTD.
CLARENDON HOUSE 2 CHURCH STREET
HAMILTON
D0
HM11
BERMUDA
false
true
false
false
CHIEF OPERATING OFFICER
0
Class A Common Share
2024-04-08
4
M
0
2726
A
126825
D
Class A Common Share
2024-04-08
4
F
0
801
17.90
D
126024
D
Share Option
18.06
2024-04-04
4
A
0
36300
0
A
2034-03-31
Class A Common Share
36300
36300
D
Performance Share Unit
2024-04-04
4
A
0
5585
0
A
2034-03-31
Class A Common Share
5585
5585
D
Restricted Share Unit
2024-04-04
4
A
0
6981
0
A
Class A Common Share
6981
12299
D
Restricted Share Unit
2024-04-08
4
M
0
2726
0
D
Class A Common Share
2726
9573
D
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal month installments thereafter. The vesting commencement date is April 1, 2024.
Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.
Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply.
The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter.
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.
/s/ Madelyn Zeylikman, Attorney-in-Fact
2024-04-08